Eligo Bioscience from France secures $30M in Series B Funding to revolutionize Genetic Medicines
Eligo Bioscience, a Paris-based gene-editing company, has raised $30 million in a Series B funding round, marking a significant advancement in the field of genetic medicines. The funding round was led by Sanofi Ventures, with contributions from new investor Bpifrance (through its InnoBio 2 fund) and existing backers Khosla Ventures and Seventure Partners.
Klarytee, a UK-based cybersecurity startup founded by an immigrant entrepreneur, has successfully raised £700,000 in a pre-seed funding round. This early-stage startup, which integrates security directly into data, has garnered support from notable figures in the tech industry, including former Twitter CISO Michael Coates and former Group CEO of Bupa,

The best Articles in our Network

Previous
Next